Interní Med. 2010; 12(7-8): 361-365

Low molecular weight heparins in outpatient practice

MUDr.Petr Kessler
Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov, p. o.

The structure and function of low molecular heparins (LMWHs), their pharmacokinetics and monitoring, the most important side effects

and list of indications are described in the article, which is oriented to the outpatient practice. The selected recommendations concerning

bleeding complications, laboratory monitoring, thromboprophylaxis, treatment of venous thromboembolism and preoperative measures

in patients treated with warfarin are discussed, and special aspects of therapy with LMWHs during pregnancy are mentioned.

Keywords: low molecular weight heparin, pharmacokinetics, venous thromboembolism, preoperative management, pregnancy

Published: August 12, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kessler P. Low molecular weight heparins in outpatient practice. Interní Med. 2010;12(7-8):361-365.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lebaudy C, Hulot JS, Amoura Z, et al. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin. Pharmacol Ther. 2008; 84(3): 370-377. Go to original source... Go to PubMed...
    2. Gram J, Mercker S, Bruhn HD. Does protamine chloride neutralize low molecular weight heparin sufficiently? Thromb Res. 1988; 1, 52(5): 353-359. Go to original source... Go to PubMed...
    3. Andrassy K, Eschenfelder V, Weber E. Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride. Thromb Res. 1994; 15, 73(2): 85-93. Go to original source... Go to PubMed...
    4. Hirsh H, Bauer KA, Donati MB, et al. Parenteral Anticoagulants: American College of Chest Physicians evidencebased clinical practice guidelines (8th edition). Chest 2008; 133; 141-159. Go to original source...
    5. Firozvi K, Deveras RA, Kessler CM. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol. 2006; 81(8): 582-589. Go to original source... Go to PubMed...
    6. Ortel TL Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. Hematology 2009; 2009: 225-232. Go to original source... Go to PubMed...
    7. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 340-380. Go to original source...
    8. Garcia DA, Spyropoulos AC. Update in the treatment of venous thromboembolism. Semin Respir Crit Care Med. 2008; 29(1): 40-46. Go to original source... Go to PubMed...
    9. Verhamme P, Motte S, Claes N, et al. Current primary care practice in the diagnosis and management of patients with suspected venous thromboembolism and prescription of initiation dose of enoxaparin. Int Angiol. 2010; 29(1): 58-63. Go to PubMed...
    10. Bounameaux H, Righini M, Perrier A. Venous thromboembolism: contemporary diagnostic and therapeutic aspects. Vasa 2008; 37(3): 211-226. Go to original source... Go to PubMed...
    11. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 454-545. Go to original source...
    12. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of lowmolecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 12-26, 162(15): 1729-1735. Go to original source... Go to PubMed...
    13. Lee AYY, Levine MN, Baker RI, et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 10, 349(2): 146-153. Go to original source... Go to PubMed...
    14. Lee AY. Treatment of venous thromboembolism in cancer patients. Best Pract Res Clin Haematol. 2009; 22(1): 93-101. Go to original source... Go to PubMed...
    15. Kessler P. Prevence žilní tromboembolické nemoci v ortopedii a traumatologii. Vnitřní lékařství 2009; 55(3): 204-210. Go to PubMed...
    16. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 381-453. Go to original source...
    17. Marlovits S, Striessnig G, Schuster R, et al. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study. Arthroscopy 2007; 23(7): 696-702. Go to original source... Go to PubMed...
    18. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 28, 346(13): 975-980. Go to original source... Go to PubMed...
    19. Testroote M, Stigter W, de Visser DC, et al. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. Cochrane Database Syst Rev. 2008; 8(4): CD006681. Go to original source... Go to PubMed...
    20. Ettema HB, Kollen BJ, Verheyen CC, et al. Prevention of venous thromboembolism in patients with immobilization of the lower extremities: a meta-analysis of randomized controlled trials. J Thromb Haemost. 2008; 6(7): 1093-1098. Go to original source... Go to PubMed...
    21. Bergmann JF, Cohen AT, Tapson VF, et al. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost. 2010; 31, 103(4): 736-748. Go to original source... Go to PubMed...
    22. Hájek R, Adam Z, Maisnar V, et al. Doporučení vypracované Českou myelomovou skupinou a Myelomovou sekcí České hematologické společnosti a Slovenskou myelómovou společností pro diagnostiku a léčbu mnohočetného myelomu. Transfuse a hematologie dnes 2009; 15(suppl 2): 5-80.
    23. Kessler P. Profylaxe a léčba tromboebolické nemoci v onkologii. Vnitřní lékařství 2009; 55(3): 219-222. Go to PubMed...
    24. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 299-339. Go to original source...
    25. Iturbe-Alessio I, Fonseca MC, Mutchinik O, et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med. 1986; 27, 315(22): 1390-1393. Go to original source... Go to PubMed...
    26. Sherer DM, Anyaegbunam A, Onyeije C. Antepartum fetal intracranial hemorrhage, predisposing factors and prenatal sonography: a review. Am J Perinatol. 1998; 15(7): 431-441. Go to original source... Go to PubMed...
    27. Penka M, Dulíček P, Binder T. Antitrombotická profylaxe v těhotenství. Vnitřní lékařství 2009; 55(3): 211-215. Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.